title: Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.
abstract: Gastric cancer remains a major health burden worldwide. There is near-universal agreement that neoadjuvant chemotherapy (NAC) is a preferred management for locally advanced gastric cancer (LAGC). However, the optimal approach for an individual patient is still not clear and remains controversial, which could be at least partly explained by the lack of predictive tools. The ability to predict chemosensitivity from NAC in routine clinical practice is difficult and is an area of intense investigation, especially in the Precision-Medicine Era. Available consistent evidence suggests that a favorable tumor histopathological response to NAC may be a useful positive prognostic marker in gastric cancer. Hence, it is reasonable to speculate that making the histopathological response from NAC predictable will dramatically facility the NAC and improve patients' outcome. This review provides an overview on the current status of predictive biomarkers for histopathological response from NAC in LAGC, including clinicopathological variables, imaging and molecular testing. Furthermore, limitations and future perspectives are also discussed.
authors: Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Jichun
authors: J
authors: Zhou
authors: Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Jianguo
authors: J
authors: Shen
authors: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA.
authors: Benjamin J
authors: BJ
authors: Seifer
authors: Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
authors: Shaojie
authors: S
authors: Jiang
authors: Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Ji
authors: J
authors: Wang
authors: Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Hanchu
authors: H
authors: Xiong
authors: Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Lingmin
authors: L
authors: Xie
authors: Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Linbo
authors: L
authors: Wang
authors: Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.|Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
authors: Xinbing
authors: X
authors: Sui
mesh_terms: D014408:Biomarkers, Tumor; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D000074141:Circulating Tumor DNA; D005820:Genetic Testing / Q000379:methods; D014644:Genetic Variation; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D064847:Multimodal Imaging; D020360:Neoadjuvant Therapy / Q000009:adverse effects; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating; D011379:Prognosis; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D000074141:Circulating Tumor DNA
keywords: chemosensitivity; gastric cancer; histopathological response; neoadjuvant chemotherapy; predictive biomarker